Adolors ENTEREG first-one fourth net revenue increases to $5.

Net shipments of ENTEREG in the first quarter of 2009 were $2.0 million. ‘The first one fourth saw steady progress over the panel at Adolor,’ said Michael R. Dougherty, President and CEO. ‘Inside our delta opioid receptor agonist system, we have concluded enrollment in our Stage 2a proof-of-concept study of ADL5859 and ADL5747 in osteoarthritis patients and be prepared to present top series results from this study in mid-2010. We also were pleased to initiate in the 1st quarter our Phase 2a proof-of-concept study of ADL5747 in post-herpetic neuralgia and enrollment is currently well underway. Inside our opioid bowel dysfunction program, both ADL7445 and ADL5945 are being evaluated in patients with OBD now. We are pleased with the results observed to date in our Phase 1 system and anticipate initiating proof-of-concept testing later on this season.’ ‘Progress continues with ENTEREG as well,’ added Mr.We are very much looking towards this co-operation’ stated Michael Schlenk, CEO of ProBioGen. About AFFiRiS AG.

AMS earns ISO 9001: 2008 certification for quality from TUV Rheinland of THE UNITED STATES Littleton-based Alcohol Monitoring Systems, Inc. , the world’s largest supplier of high-tech alcoholic beverages monitoring technologies, offers been awarded ISO 9001: 2008 qualification by TUV Rheinland of THE UNITED STATES, based on the standards established by the International Companies of Standardization . The certification, that involves an arduous, multi-phase qualification audit, is based on the ISO global regular for quality administration systems. The certification means that AMS has achieved the highest global requirements for the design, development, and management of AMS the business, in addition to its products.